This article is authored by Pratik Arya, CEO & co-founder, Finnacle Institute.
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate ...
Researchers developed a compound that protects the liver after small bowel resection in mice. The drug improved nutrient absorption, reduced fibrosis, and avoided systemic side effects, offering hope ...
SB Nation on MSN
NBA Draft Prospect: Caleb Wilson
Cognition vs function, what prevails historically?
Thank you so much, Jon, and thank you all for joining us today. First, we are continuing to prioritize customer growth and ...
Q4 2025 Earnings Call March 19, 2026 5:00 PM EDTCompany ParticipantsYojin Yoon - Vice President of OperationsJoshua ...
Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 ...
Q4 2025 Earnings Call March 16, 2026 8:00 AM EDTCompany ParticipantsKristal Li - Investor Relations ManagerYan Li - Chairman, ...
Stevens Point Journal on MSN
Meet candidates vying for 4 seats on the Stevens Point School Board
Incumbents Ted Kowalski, Gee Pope, Elizabeth Potter-Nelson and Alex Sommers will face challengers Miguel Campos, Jeff Ebel ...
As funding mechanisms for sovereign debt and large assets increasingly migrate toward real-time financial infrastructure, banks are at risk of being displaced as key intermediaries in global finance.
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2025 Earnings Call Transcript March 12, 2026 HeartBeam, Inc. misses on earnings expectations. Reported EPS is $-0.15728 EPS, expectations were $-0.1375. Operator: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results